10.15.18

Aura Biosciences to Present Phase 1b/2 Clinical Data for AU-011 at AAO

Source: Aura Biosciences

Aura Biosciences announced that it will be highlighting its phase 1b/2 clinical data for AU-011, the company’s lead product candidate for the primary treatment of choroidal melanoma, in two oral presentations at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting being held October 27-30, 2018, at McCormick Place in Chicago.

“Following the positive interim results reported in July 2018 from this ongoing phase 1b/2 study evaluating AU-011 in patients with choroidal melanoma, we are pleased to be sharing these updated, 1-year results with the medical community at AAO this year,” Elisabet de los Pinos, PhD, Founder and Chief Executive Officer of Aura, said in a company news release. “There are no FDA approved therapies for the treatment of choroidal melanoma, the most common type of primary eye cancer. Patients are currently treated with radiotherapy and surgery which typically results in severe vision loss, along with a plethora of other severe adverse effects and comorbidities. If approved, AU-011 will be the first targeted therapy for the treatment of choroidal melanoma, with the potential to preserve vision and transform the treatment paradigm for these patients.”

In addition to the AAO clinical data presentations, Aura has been selected to present its innovative technology for the treatment of choroidal melanoma as part of the Innovation Showcase during the Ophthalmology Innovation Summit (OIS@AAO) taking place Thursday, October 25, 2018, at the Marriot Marquis Chicago. Dr. de los Pinos will give the presentation which will provide an update on Aura Biosciences.

Details for the oral presentations at AAO 2018:
 
Title: One-Year Results of a Phase 1b/2 Open-Label Clinical Trial of AU-011 for the Treatment of Primary Choroidal Melanoma
Presenter: Brian P. Marr, M.D., Columbia University Medical Center
Session: Ocular Oncology
Date and Time: Saturday, October 27, 2018, from 3:21 – 3:29 PM CT
Location: Room E350
 
Title: One-Year Results of a Phase 1b/2 Open-Label Clinical Trial of AU-011 for the Treatment of Primary Choroidal Melanoma
Presenter: Brian P. Marr, M.D., Columbia University Medical Center
Session: Ocular Pathology, Oncology
Date and Time: Monday, October 29, 2018, from 3:57 – 4:04 PM CT
Location: Room E350
 

 

Related Content